| Name | Title | Contact Details |
|---|
Founded in 2009 in France and the USA by Pierre Jerome and Stephane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 80,000 surgical procedures worldwide. Sixteen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these solid fundamentals and several strategic partnerships, SpineGuard has expanded its technology platform in a disruptive innovation: the « smart » pedicle screw launched late 2017 and is broadening the scope of applications in dental implantology and surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer.
Trice Medical was founded to fundamentally improve orthopedic diagnostics. Trice has pioneered fully integrated camera-enabled technologies that provide a clinical solution that is optimized for the physicians office. Our mission is to provide more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reduce the overall cost to the healthcare system.
MicroOptx is an early stage medical device company that is building a platform technology to shunt aqueous humor from the anterior chamber to the surface of the eye. Our mission is to change the way the World treats glaucoma – halting the devastating effects of this progressive disease. MicroOptx is led by recognized medical, industry and financial veterans who are dedicated towards preventing blindness.
Annex Ventures is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vermillion`s vision is to become a recognized leader in the advancement of women`s health by providing innovative methods to detect, monitor and manage the treatment of gynecologic cancers and other related diseases. We will develop and commercialize high-value, multi-marker, diagnostic tests which address unmet needs in gynecologic oncology and women’s health. We will accomplish our mission through internal development, targeted acquisitions, and collaborations with leading scientific and clinical institutions. Our global commercial efforts will include direct marketing and sales activities as well as partnerships with leading companies in women’s health.